Published online Feb 10, 2015. doi: 10.5306/wjco.v6.i1.1
Peer-review started: August 17, 2014
First decision: November 3, 2014
Revised: November 19, 2014
Accepted: December 3, 2014
Article in press: December 10, 2014
Published online: February 10, 2015
Processing time: 172 Days and 6.5 Hours
The surgical treatment of localized breast cancer has become progressively less aggressive over the years. The management of the axillary lymph nodes has been modified by the introduction of sentinel lymph node biopsy. Axillary dissection can be avoided in patients with sentinel lymph node negative biopsies. Based on randomized trials data, it has been proposed that no lymph node dissection should be carried out even in certain patients with sentinel lymph node positive biopsies. This commentary discusses the basis of such recommendations and cautions against a general omission of lymph node dissection in breast cancer patients with positive sentinel lymph node biopsies. Instead, an individualized approach based on axillary tumor burden and biology of the cancer should be considered.
Core tip: Management of the axilla in breast cancer has been modified by the introduction of sentinel lymph node biopsy. Axillary dissection can be avoided in sentinel lymph node negative patients. More recently, it has been proposed that lymph node dissection could be avoided even in patients with sentinel lymph node positive biopsies. The basis of such proposals is discussed here and caution is advised against a universal omission of lymph node dissection in breast cancer patients with positive sentinel lymph node biopsies. Instead, an individualized approach based on axillary tumor burden and biology of the cancer should be considered.